Elutia Reports Q3 2026 Revenue Growth Driven by Cardiovascular Segment
Elutia (ELUT) reported third-quarter 2026 net sales of $1.1 million, representing a 20.4% year-over-year increase fueled primarily by its cardiovascular business. While the company reported an adjusted EBITDA loss of $5.6 million due to increased R&D spending on the NXT-41 and NXT-41x programs, net loss improved to $1.3 million compared to $3.9 million in the prior year, aided by income from discontinued operations following recent business divestitures. The company is heavily focused on the regulatory path for its NXT-41 platform, with FDA clearance expected in Q4 2026. Elutia has strengthened its liquidity position with $29.1 million in cash and equivalents and has secured $26 million in nondilutive funding to support operations through its anticipated first full year of commercial launch.
Topics: cardiovascular business performance cash position gross margin expansion net sales growth R&D investment